Tumor Location and Survival Outcomes in Adult Patients with Supratentorial Glioblastoma by Levels of Toll-Like Receptor 9 Expression

Mu, Linsen; Wang, Yongzhi; Wang, Yonggang; Shang, Dewei; Tan, Fuqiang; Li, Yan; Chen, Xuzhu

doi:10.1016/j.wneu.2016.10.015

Cited by 12 publications

(9 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although they are not generally present in the CNS, they can be recruited in response to pathological stimuli [ 175 ]. Interestingly, in glioma, the TLR9 expression by pDCS is downregulated and both TLR9 and the manipulation of DC activity are proposed to be attractive targets in GBM immunotherapy [ 174 , 175 , 176 , 177 ].…”

Section: Role Of Tspo In Hallmarks Of Gbmmentioning

confidence: 99%

The Role of Translocator Protein TSPO in Hallmarks of Glioblastoma

Ammer

Vollmann-Zwerenz

Ruf

et al. 2020

Cancers

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most fatal primary brain cancer in adults. Despite extensive treatment, tumors inevitably recur, leading to an average survival time shorter than 1.5 years. The 18 kDa translocator protein (TSPO) is abundantly expressed throughout the body including the central nervous system. The expression of TSPO increases in states of inflammation and brain injury due to microglia activation. Not least due to its location in the outer mitochondrial membrane, TSPO has been implicated with a broad spectrum of functions. These include the regulation of proliferation, apoptosis, migration, as well as mitochondrial functions such as mitochondrial respiration and oxidative stress regulation. TSPO is frequently overexpressed in GBM. Its expression level has been positively correlated to WHO grade, glioma cell proliferation, and poor prognosis of patients. Several lines of evidence indicate that TSPO plays a functional part in glioma hallmark features such as resistance to apoptosis, invasiveness, and proliferation. This review provides a critical overview of how TSPO could regulate several aspects of tumorigenesis in GBM, particularly in the context of the hallmarks of cancer proposed by Hanahan and Weinberg in 2011.

show abstract

Section: Role Of Tspo In Hallmarks Of Gbmmentioning

confidence: 99%

The Role of Translocator Protein TSPO in Hallmarks of Glioblastoma

Ammer

Vollmann-Zwerenz

Ruf

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…A correlation between resected tumor volume and prognosis has been demonstrated. The aim is to resect as much as possible while paying attention to protect sensitive structures (7,8). Modalities such as MR-tractography, MR-perfusion used in preoperative planning make a significant contribution to the morbidity and prognosis due to the predetermination of the area of resection.…”

Section: Discussionmentioning

confidence: 99%

“…The factor limiting the surgical approach to these areas is the potential magnitude of neurological loss. Safe total resection is the surgical goal in glial tumors, and the amount of resection is one of the most important factors determining prognosis (6)(7)(8). The aim of our study was to examine the effect of tumor location on postsurgical residue rate in 99 patients.…”

Section: Introductionmentioning

confidence: 99%

Retrospective Analysis of Tumor Location with Residue Rates in High-grade Glial Tumors

Seyithanoğlu¹,

Dündar²,

Kitiş³

et al. 2020

eamr

View full text Add to dashboard Cite

Glioblastoma is the most commonly seen and quite an aggressive type of primary brain tumor. Location of the tumor, age, and sex are important prognostic factors. The aim of this study was to present the retrospective data about glioblastoma patients in which location of glioblastoma and calculation of residual tumor tissue was performed at our clinic. Methods: Tumor location, age and sex distributions, and residue presence in control magnetic resonance imaging (MRI) of 99 patients treated at our clinic within the last two years with a high-grade glial tumor were examined retrospectively. Variables included in the analysis were demographic data and the presence of residue on the control MRI within 24 hours. Chi-square test was used for comparisons. The data were analyzed by SPSS version 24.0 package program. Results: Of a total of 99 glioblastomas, the male/female ratio was 2:1, the average age of the patients was 54±37 (minimum: 18, maximum: 88; standard deviation: 15.08). In MRI, tumor was located at the frontal and temporal lobes with maximal percentile. In 55 of the cases, total resection was seen. In 38 of the cases, residue under 10% was seen, and in 6 of the cases, residual mass over 10% was seen. Relationship of tumor location with residual mass was not statistically significant (p=0.562). Conclusion: The aim of neurosurgery in glioblastomas is surgical excision to remove as much tumor as possible with minimal neurological deficit. Preoperative characterization of the tumor through current imaging methods makes a significant contribution to mortality and morbidity. New prognostic parameters are needed based on new surgical approaches and imaging techniques.

show abstract

“…derin veya yüzeyel yerleşimli tümörlerin prognostik etkisi olmadığını bildirdi (10). Literatürde GBM'in sağ-sol tümör lokasyonu ve sağ kalım ilişkisinin araştırıldığı tek çalışmada, tümör sağ veya sol lob yerleşiminin PFS ve OS üzerine etkili olmadığı gösterilmiştir (14). Bu çalışmalardan farklı olarak bizim çalışmamızda tümörü sol hemisferde lokalize olan hastalarda OS daha uzun izlendi.…”

Section: Discussionunclassified

Survival and Treatment Outcome Differences in Glioblastoma Multiforma Patients aged 65 years and over after Gross Total Resection Compared to Patients who did not undergo Gross Total Resection of a Single Lesion

Salim¹,

Yıldız²

2019

Akd Med J

View full text Add to dashboard Cite

Amaç: Çalışmada, 65 yaş ve üzeri, tek odak glioblastome multiforme tanılı kemoradyoterapi almış hastalarda primer tümörün gross total rezeksiyonu uygulanan ve uygulanmayan gruplarda kemoradyoterapiye yanıtların ve sağ kalımların karşılaştırılmıştır. Gereç ve Yöntemler: 65 yaş ve üzeri, histolojik olarak kanıtlanmış glioblastome multiforme tanısı olan hastaların tek merkez verileri retrospektif olarak değerlendirilmiştir. Gross total rezeksiyon uygulanmış ve uygulanmamış hastaların radyoterapi eş zamanlı temozolamid tedavilerini tamamlamış olanlar tedavi yanıtları, progresyonsuz sağkalım, rekürrensiz sağkalım ve genel sağ kalım açısından analiz edilmiştir. Bulgular: Çalışmaya 55 hasta dahil edilmiştir. Genel yanıt oranı her iki grupta benzer izlendi (%23,5 vs %23,8, p=0,984). Her iki grupta medyan genel sağkalım 13 ay iken (p=0,645); gross total rezeksiyon uygulanan kolda medyan rekürrenssiz sağ kalım 8 ay; gross total rezeksiyon uygulanmayan grupta medyan progresyonsuz sağ kalım 6 aydı. Median tümör çapı her iki grupta da 4 cm idi (p=0,875). Rekürrens veya progresyon sonrası kurtarma tedavisi alabilen hasta oranı benzerdi. Univariate analizde, cinsiyet (HR 1,061 [%95CI 0,589-1,912]; p=0,844), yaş (HR 0,992 [%95CI 0,538-1,831]; p=0,980), tümör çapı (HR 0,740 [%95CI 0,411-1,333]; p=0,316), primerin gross total rezeksiyonu (HR 0,869 [%95CI 0,470-1,607]; p=0,653) genel sağ kalım üzerine etkili izlenmezken, sol beyin tümörlerinde (HR 2,183 [%95CI 1,204-3,957]; p=0,010) genel sağ kalım daha uzun izlendi. Sonuç: Altmış beş yaş ve üstü tek odak glioblastoma multiforme hastalarında gross total rezeksiyon uygulanan ve uygulanmayan gruplar arasında kemoradyoterapi tedavi yanıt farkı ve genel sağ kalım farkı izlenmemiştir.

show abstract

Tumor Location and Survival Outcomes in Adult Patients with Supratentorial Glioblastoma by Levels of Toll-Like Receptor 9 Expression

Cited by 12 publications

References 19 publications

The Role of Translocator Protein TSPO in Hallmarks of Glioblastoma

The Role of Translocator Protein TSPO in Hallmarks of Glioblastoma

Retrospective Analysis of Tumor Location with Residue Rates in High-grade Glial Tumors

Survival and Treatment Outcome Differences in Glioblastoma Multiforma Patients aged 65 years and over after Gross Total Resection Compared to Patients who did not undergo Gross Total Resection of a Single Lesion

Contact Info

Product

Resources

About